Ashwagandha (Withania somnifera) Reverses β-Amyloid1-42 Induced Toxicity in Human Neuronal Cells: Implications in HIV-Associated Neurocognitive Disorders (HAND)

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Kurapati, Kesava Rao Venkata ^a   Atluri, Venkata Subba Rao ^a   Samikkannu, Thangavel ^a   Nair, Madhavan P N ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMYLOID BETA PROTEIN[1-42]; CHLOROFORM; METHANOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; WITHANIA SOMNIFERA EXTRACT;

ARTICLE; BRAIN NERVE CELL; CELL DENSITY; CELL GROWTH; CELL LOSS; CELL VIABILITY; CLADISTICS; CONFOCAL MICROSCOPY; DENDRITIC SPINE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PLANT ROOT; WITHANIA SOMNIFERA;

AMYLOID BETA-PEPTIDES; CELL LINE; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DENDRITES; HIV INFECTIONS; HUMANS; HYDRO-LYASES; MASS SPECTROMETRY; NERVOUS SYSTEM DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PLANT EXTRACTS; PPAR GAMMA; WITHANIA;

EID: 84885805283     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077624     Document Type: Article

References (75)

1. Iversen LL, Mortishire-Smith RJ, Pollack SJ, Shearman MS, (1995) The toxicity in vitro of β-amyloid protein. Biochem J 311: 1-16. PubMed: 7575439.
2. Zhang C, Tanzi RE, (2012) Natural modulators of amyloid-beta precursor protein processing. Curr Alzheimer Res 9: 1-8. doi:10.2174/156720512799015082. PubMed: 22329648.
3. Hardy J, (2006) A hundred years of Alzheimer's disease research. Neuron 52: 3-13. doi:10.1016/j.neuron.2006.09.016. PubMed: 17015223.
4. Ross CA, Poirier MA, (2004) Protein aggregation and neurodegenerative disease. Nat Med 10: S10-S17. doi:10.1038/nm1066. PubMed: 15272267.
5. Citron M, (2004) Strategies for disease modification in Alzheimer's disease. Nature. Rev Neurosci 5: 677-685. doi:10.1038/nrn1495.
6. Citron M, (2010) Alzheimer's disease: Strategies for disease modification. Nat Rev Drug Discov 9: 387-398. doi:10.1038/nrd2896. PubMed: 20431570.
7. Bertram L, Lill CM, Tanzi RE, (2010) The genetics of Alzheimer disease: back to the future. Neuron 68: 270-281. doi:10.1016/j.neuron.2010.10.013. PubMed: 20955934.
8. Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, et al. (2013) Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. doi:10.1016/j.neuron.2013.04.014.
9. Tanzi RE, Bertram L, (2005) Twenty years of the Alzheimer's disease hypothesis: a genetic perspective. Cell 120: 545-555. doi:10.1016/j.cell.2005.02.008. PubMed: 15734686.
10. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, et al. (2006) Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63: 168-174. doi:10.1001/archpsyc.63.2.168. PubMed: 16461860.
11. Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, et al. (2005) Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 19: 407-411. doi:10.1097/01.aids.0000161770.06158.5c. PubMed: 15750394.
12. Esiri MM, Biddolph SC, Morris CS, (1998) Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg, Psychiatry 65: 29-33. doi:10.1136/jnnp.65.1.29. PubMed: 9667557.
13. Soontomniyomkij V, Moore DJ, Soontomniyomkij B, Tatro ET, Umlauf A, et al. (2012) Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers. AIDS 26: 2327-2335. doi:10.1097/QAD.0b013e32835a117c. PubMed: 23018443.
14. Giunta B, Ehrhart J, Obregon DF, Lam L, Le L, (2011) Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increases its production by neurons: implications for HIV-associated neurocognitive disorders. Molecular Brain 4: 23-29. doi:10.1186/1756-6606-4-23. PubMed: 21649911.
15. Shearman MS, Ragan CI, Iversen LL, (1994) Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of 1-amyloid-mediated cell death. Proc Natl Acad Sci U_S_A 91: 1470-1474. doi:10.1073/pnas.91.4.1470. PubMed: 8108433.
16. Kulkarni SK, Dhir A, (2008) Withania somnifera: An Indian ginseng. Prog Neuropsychopharmacol Biol Psychiatry 32: 1093-1105. doi:10.1016/j.pnpbp.2007.09.011. PubMed: 17959291.
17. Mishra LC, Singh BB, Dagenais S, (2000) Scientific basis for the therapeutic use of Withania somnifera (Ashwagandha): a review. Altern Med Rev 5: 334-346. PubMed: 10956379.
18. Kuboyama T, Tohda C, Komatsu K, (2005) Neurite regeneration and synaptic reconstruction induced by Withanolide A. Br J Pharmacol 144: 961-971. doi:10.1038/sj.bjp.0706122. PubMed: 15711595.
19. Jain S, Shukla SD, Sharma K, Bhatnagar M, (2001) Neuroprotective effects of Withania somnifera Dunn.in hippocampal sub-regions of female albino rat. Phytotherapy Research 15: 544-548.
20. Sankar SR, Manivasagam T, Krisnamurt A, Ramanathan M, (2007) The neuroprotective effect of Withania somnifera root extract in MPTP-intoxicated mice: An analysis of behavioural and biochemical variables. Cell Mol Biol Lett 12: 473-481. doi:10.2478/s11658-007-0015-0. PubMed: 17415533.
21. Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, et al. (2012) Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci U_S_A 109: 3510-3515. doi:10.1073/pnas.1112209109. PubMed: 22308347.
22. Wogulis M, Wright S, Cunningham D, Chilcote T, Powell K, et al. (2005) Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J Neurosci 25: 1071-1080. doi:10.1523/JNEUROSCI.2381-04.2005. PubMed: 15689542.
23. Panandiker A, Maru GB, Rao KVK, (1994) Dose-response effects of malachite green on free radical formation, lipid peroxidation and DNA damage in Syrian hamster embryo cells and their modulation by antioxidants. Carcinogenesis 15: 2445-2448. doi:10.1093/carcin/15.11.2445. PubMed: 7955089.
24. Rao KVK, Samikkannu T, Dakshayani KB, Zhang X, Sathaye SS, et al. (2012) Chemopreventive potential of an ethyl acetate fraction from Curcuma longa is associated with upregulation of p57kip2 and Rad9 in the PC-3M prostate cancer cell line. Asian Pac J Cancer Prev 13: 1031-1038. doi:10.7314/APJCP.2012.13.3.1031. PubMed: 22631633.
25. Panandiker A, Fernandes C, Rao KVK, (1992) The cytotoxic properties of malachite green are associated with the increased demethylase, aryl hydrocarbon hydroxylase and lipid peroxidation in primary cultures of Syrian hamster embryo cells. Cancer Lett 67: 93-101. doi:10.1016/0304-3835(92)90131-E. PubMed: 1483270.
26. Michaelis ML, Ansar S, Chen Y, Reiff ER, Seyb KI, et al. (2005) β-Amyloid -induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents. J Pharmacol Exp Ther 312: 659-668. PubMed: 15375176.
27. Yankner BA, Duffy LK, Kirschner DA, (1990) Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 250: 279-282. doi:10.1126/science.2218531. PubMed: 2218531.
28. Kumar S, Seal CJ, Howes MJR, Kite GC, Okello EJ, (2010) In vitro protective effects of Withania somnifera (L.) Dunal root extract against hydrogen peroxide and b-amyloid (1-42)-induced cytotoxicity in differentiated PC12 Cells. Phytotherapy Research 24: 1567-1574.
29. London JA, Biegel D, Pachter JS, (1996) Neurocytopathic effects of β-amyloid-stimulated monocytes: A potential mechanism for central nervous system damage in Alzheimer disease. Proc Natl Acad Sci U_S_A 93: 4147-4152. doi:10.1073/pnas.93.9.4147. PubMed: 8633031.
30. Rao KVK, Samikkannu T, Dakshayani KB, Zainulabedin SM, Gandhi N, et al. (2012) Combinatorial cytotoxic effects of Curcuma longa and Zingiber officinale on the PC-3M prostate cancer cell line. J Basic Clin Physiol Pharmacol 23: 139-146. PubMed: 23072849.
31. Atluri VSR, Kanthikeel SP, Pichili VBR, Yndart A, Nair MPN, (2013) Human synaptic plasticity gene expression profile and dendritic spine density changes in HIV-infected human CNS cells: role in HIV-associated neurocognitive disorders (HAND). PLOS ONE 8(4):: e61399. doi:10.1371/journal.pone.0061399. PubMed: 23620748.
32. Ji HF, Zhang HY, (2008) Multipotent natural agents to combat Alzheimer's disease. Functional spectrum and structural features. Acta Pharmacol Sin 29: 143-151. doi:10.1111/j.1745-7254.2008.00752.x. PubMed: 18215342.
33. Williams P, Sorribas A, Howes MJ, (2011) Natural products as a source of Alzheimer's drug leads. Nat Prod Rep 28: 48-77. doi:10.1039/c0np00027b. PubMed: 21072430.
34. Newman DJ, Cragg GM, (2007) Natural products as source of new drugs over the last 25 years. J Nat Prod 70: 461-477. doi:10.1021/np068054v. PubMed: 17309302.
35. Smith DL, Pozueta J, Gong B, Arancio O, Shelanski M, (2009) Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc Natl Acad Sci U S A 106: 16877-16882. doi:10.1073/pnas.0908706106. PubMed: 19805389.
36. Van Marum RJ, (2008) Current and future therapy in Alzheimer's disease. Fundamentals of Clinical Pharmacology 22: 265-74.
37. Lyketsos CG, Colenda CC, Beck C, Blank K, Doraiswamy MP, et al. (2006) Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry 14: 561-572. doi:10.1097/01.JGP.0000221334.65330.55. PubMed: 16816009.
38. Ahmad M, Saleem S, Ahmad AS, (2005) Neuroprotective effects of Withania somnifera on 6-hydroxydopamineinduced Parkinsonism in rats. Hum Exp Toxicol 24: 137-147. doi:10.1191/0960327105ht509oa. PubMed: 15901053.
39. Archana R, Namasivayam A, (1999) Antistressor effect of Withania somnifera. J Ethnopharmacol 64: 91-93. PubMed: 10075127.
40. Scartezzini P, Speroni E, (2000) Review on some plants of Indian traditional medicine with antioxidant activity. J Ethnopharmacol 71: 23-43. doi:10.1016/S0378-8741(00)00213-0. PubMed: 10904144.
41. Tohda C, Kuboyama T, Komatsu K, (2000) Dendrite extension by methanol extract of Ashwagandha (roots of Withania somnifera) in SK-N-SH cells. NeuroReport 11: 1981-1985. doi:10.1097/00001756-200006260-00035. PubMed: 10884056.
42. Zhao J, Nakamura N, Hattori M, Kuboyama T, Tohda C, et al. (2002) Withanolide derivatives from the roots of Withania somnifera and their neurite outgrowth activities. Chem Pharm Bull 50: 760-765. doi:10.1248/cpb.50.760. PubMed: 12045329.
43. Kuboyama T, Tohda C, Komatsu K, (2005) Neuritic regeneration and synaptic reconstruction induced by withanolide A. Br J Pharmacol144: 961-971. doi:10.1038/sj.bjp.0706122. PubMed: 15711595.
44. Grandhi A, Mujumdar AM, Patwardhan B, (1994) A comparative pharmacological investigation of Ashwagandha and Ginseng. J Ethnopharmacol 44: 131-135. doi:10.1016/0378-8741(94)01119-2. PubMed: 7898119.
45. Behl C, Davis J, Cole GM, Schubert D, (1992) Vitamin E protects nerve cells from amyloid β protein toxicity. Biochem Biophys Res Commun 186: 944-950. doi:10.1016/0006-291X(92)90837-B. PubMed: 1497677.
46. Koh JY, Yang LL, Cotman CW, (1990) β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 533: 315-320. doi:10.1016/0006-8993(90)91355-K. PubMed: 2289145.
47. Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, et al. (1993) Apoptosis is induced by β-Amyloid in cultured nervous system neurons. Proc Natl Acad Sci U_S_A 90: 7951-7955. doi:10.1073/pnas.90.17.7951. PubMed: 8367446.
48. Deshpande A, Mina E, Glabe C, Busciglio J, (2006) Different conformations of amyloid β induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 26: 6011-6018. doi:10.1523/JNEUROSCI.1189-06.2006. PubMed: 16738244.
49. Behl C, Davis JB, Lesley R, Schubert D, (1994) Hydrogen peroxide mediates amyloid b protein toxicity. Cell 77: 817-827. doi:10.1016/0092-8674(94)90131-7. PubMed: 8004671.
50. Behl C, (1997) Amyloid b-protein toxicity and oxidative stress in Alzheimer's disease. Cell Tissue Res 290: 471-480. doi:10.1007/s004410050955. PubMed: 9369525.
51. Bhatnagar M, Sharma D, Salvi M, (2009) Neuroprotective effects of Withania somnifera Dunal.: A possible mechanism. Neurochemistry Res 34: 1975-1983. doi:10.1007/s11064-009-9987-7. PubMed: 19444606.
52. Greenlund LJS, Deckwerth TL, Johnson EM Jr, (1995) Superoxide dismutase delays neuronal apoptosis: A role for reactive oxygen species in programmed neuronal death. Neuron 14: 303-315. doi:10.1016/0896-6273(95)90287-2. PubMed: 7857640.
53. Canevari L, Abramov AY, Duchen MR, (2004) Toxicity of Amyloid β Peptide: Tales of calcium, mitochondria, and oxidative stress. Neurochemistry Res 29: 637-650. doi:10.1023/B:NERE.0000014834.06405.af.
54. Bhattacharya A, Ghosal S, Bhattacharya SK, (2001) Anti-oxidant effect of Withania somnifera glycowithanolides in chronic foots hock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum. J Ethnopharmacol 74: 1-6. doi:10.1016/S0378-8741(00)00309-3. PubMed: 11137343.
55. Schliebs R, Liebmann A, Bhattacharya SK, Kumar A, Ghosal S, et al. (1997) Systemic administration of defined extracts from Withania somnifera (Indian Ginseng) and Shilajit differentially affects cholinergic but not glutamatergic and GABAergic markers in rat brain. Neurochem Int 30: 181-190. doi:10.1016/S0197-0186(96)00025-3. PubMed: 9017665.
56. Houghton PJ, Howes MJ Jr, (2005) Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease. Neuro Signals 14: 6-22. doi:10.1159/000085382. PubMed: 15956811.
57. Vinutha B, Prashanth D, Salma K, (2007) Screening of selected Indian medicinal plants for acetylcholinesterase inhibitory activity. J Ethnopharmacol 109: 359-363. doi:10.1016/j.jep.2006.06.014. PubMed: 16950584.
58. Shirotani K, Tsubuki S, Iwata N, Takaki Y, Harigaya W, et al. (2001) Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J Biol Chem 276: 21895-21901. doi:10.1074/jbc.M008511200. PubMed: 11278416.
59. Eckman EA, Reed DK, Eckman CB, (2001) Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J Biol Chem 276: 24540-24548. doi:10.1074/jbc.M007579200. PubMed: 11337485.
60. Hu JG, Igarashi A, Kamata M, Nakagawa H, (2001) Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); Retards A beta aggregation, deposition, fibril formation, and inhibits cytotoxicity. J Biol Chem 276: 47863-47868. PubMed: 11604391.
61. Van Nostrand WE, Porter M, (1999) Plasmin cleavage of the amyloid beta-protein: Alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry 38: 11570-11576. doi:10.1021/bi990610f. PubMed: 10471309.
62. Yan P, Hu XY, Song HW, Yin KJ, Bateman RJ, et al. (2006) Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem 281: 24566-24574. doi:10.1074/jbc.M602440200. PubMed: 16787929.
63. Mohamed A, Posse de Chaves E, (2011) Aβ internalization by neurons and glia. Int J Alzheimers Dis. 12: 79-84.
64. Wirths O, Bayer TA, (2012) Intraneuronal Aβ accumulation and neurodegeneration: lessons from transgenic models. Life Sci 91: 1148-1152. doi:10.1016/j.lfs.2012.02.001. PubMed: 22401905.
65. Ohyagi Y, Asahara H, Chui DH, Tsuruta Y, Sakae N, et al. (2005) Intracellular Abeta42 activates p53 promoter:a pathway to neurodegeneration in Alzheimer's disease. FASEB J 19: 255-257. PubMed: 15548589.
66. Ohyagi Y, Tabira T, (2006) Intracellular amyloid beta-protein and its associated molecules in the pathogenesis of Alzheimer'sdisease. Mini Rev Med Chem 6: 1075-1080. doi:10.2174/138955706778560175. PubMed: 17073707.
67. Ohyagi Y, (2008) Intracellular amyloid beta-protein as a therapeutic target for treating Alzheimer's disease. Curr Alzheimer Res 5: 555-561. doi:10.2174/156720508786898514. PubMed: 19075582.
68. Bailey JA, Maloney B, Ge YW, Lahiri DK, (2011) Functional activity of the novel Alzheimer's amyloid β-peptide interacting domain (AβID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis. Gene 488: 13-22. doi:10.1016/j.gene.2011.06.017. PubMed: 21708232.
69. Gandy S, (2005) The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest 115: 1121-1129. doi:10.1172/JCI25100. PubMed: 15864339.
70. Mandrekar-Colucci S, Colleen KJ, Landreth GE, (2012) Mechanisms underlying the rapid peroxisome proliferator-activated receptor γ mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci 32: 10117-10128. doi:10.1523/JNEUROSCI.5268-11.2012. PubMed: 22836247.
71. Chawla A, (2010) Control of macrophage activation and function by PPARs. Circ Res 106: 1559-1569. doi:10.1161/CIRCRESAHA.110.216523. PubMed: 20508200.
72. Chinetti-Gbaguidi G, Baron M, Bouhlel MA, Vanhoutte J, Copin C, et al. (2011) Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARgamma and LXRalpha pathways. Circ Res 108: 985-995. doi:10.1161/CIRCRESAHA.110.233775. PubMed: 21350215.
73. Gordon S, (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23-35. doi:10.1038/nri978. PubMed: 12511873.
74. Mandrekar-Colucci S, Landreth GE, (2010) Microglia and inflammation in Alzheimer's disease. CNS Neurol Disord- Drug Targets 9: 156-167. doi:10.2174/187152710791012071. PubMed: 20205644.
75. Mosser DM, Edwards JP, (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969. doi:10.1038/nri2448. PubMed: 19029990.